Loxo Oncology: Loxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

(marketscreener.com) INDIANAPOLIS, Oct. 4, 2023 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company , today announced that preclinical data for agents targeting KRAS G12D, multiple oncogenic KRAS mutations and Nectin-4, will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place...https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Loxo-Lilly-Unveils-Three-New-Oncology-Programs-at-2023-AACR-NCI-EORTC-International-Conference-on-Mo-44984070/?utm_medium=RSS&utm_content=20231004